Compare General Dynamics Corporation (GD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Incyte Corporation — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: General Dynamics Corporation is far larger — about 3.9× Incyte Corporation's market cap, and General Dynamics Corporation pays a 1.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Incyte Corporation for 33 Days on average.
| GD | INCY | |
|---|---|---|
Market Cap | $89.26B | $22.85B |
Volume | 1,496,273 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $395.97 | $129.93 |
52-Week Low | $312.53 | $83.80 |
Typical Hold Time | 85 Days | 33 Days |
Enterprise Value | $94.40B | $18.35B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, up 1.0% with strong fundamental performance including three consecutive quarterly earnings beats and robust 2025 revenue of $52.55 billion. The stock shows bearish technical signals despite positive analyst sentiment with a $420.57 consensus price target representing 27.5% upside potential. Defense sector tailwinds from Pentagon spending and dividend stability support the investment case.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.12, P/S 1.65) and strong profitability metrics (ROE 17.8%, net margin 8.18%). Key risks include defense budget volatility and technical weakness, but the company's consistent earnings performance and analyst support suggest potential for medium-term appreciation.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
